Alpha1H Patent granted in Europe

By November 25, 2020 October 31st, 2021 No Comments

Press Release, Lund November 25, 2020

Hamlet Pharma AB has today successfully secured patent protection in Europe for its lead clinical candidate, Alpha1H. This protection is granted as European patent number EP 3618848 B1, which will remain valid until May 14, 2038.

Alpha1H is currently used in clinical trials in patients with bladder cancer. With this patent, Hamlet Pharma AB continues to expand it’s intellectual property portfolio in areas where its key products show benefit. Following this success at the European Patent Office, where the claims of EP 3618848 B1 were readily accepted for grant, Hamlet Pharma AB plans to seek equivalent protection in further key countries around the world.

This demonstrates the uniqueness of the innovation and the opportunities Alpha1H may offer cancer patients” says Catharina Svanborg, CMO and chairman of the board of Hamlet Pharma Ltd.

Alpha1H is our lead drug candidate and this is an important milestone to secure long-term protection in Europe” says Mats Persson, CEO of Hamlet Pharma Ltd.

For more information, please contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49

Mats Persson, CEO Hamlet Pharma, +46-705 17 67 57

About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.

This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact persons set out above, on November 25, 2020.

Hamlet Pharma

Author Hamlet Pharma

More posts by Hamlet Pharma

Hamlet Pharma AB

Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00